Thu, Nov 27, 2014, 1:06 AM EST - U.S. Markets closed for Thanksgiving Day

Recent

% | $
Quotes you view appear here for quick access.

Abbott Laboratories Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • monkeydozen monkeydozen Sep 30, 1999 10:44 PM Flag

    ABT

    It's full of such dreamers.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Just FYI I bought more today at the close - got
      some more at $36 1/2. Will it go down more? Possibly.
      And I'll be there buying some more if it drops to
      $34.00. Also shorted Merck today at the close. Gotta
      friend that just left Merck and went to Schering Plough.
      He says Merck WILL NOT hit meet next quarter's
      estimate and that the pipeline is not looking good.
      Massive cuts are coming at Merck. He and his supervisor
      both bailed and went to SGP. Good luck with your MRK
      investment - you'll need it.

      • 5 Replies to bartpj
      • Looks like bartbj's friends are full of good
        information. Check out his post. The day before a HUGE run up
        he's posting tips that MRK future is grim. Easy to see
        you are ALONE in that thinking. Shorted Merck on the
        close? OUCH! That was dumb! What did you lose on that
        trade? Did your ABT make up for it? hahahaha
        Let
        this be a lesson to anyone who listens to Bartbj. His
        shorts go up and his longs go sideways.

      • You are right about Merck. Got out at 65 1/2. Looks weak, you are right. It will be lower. I'll pick up some more cheaper, later.

      • and you may understand what is going on with this board.

      • So Bartbj,
        You bought 50 shares? 100 shares?
        Do tell. I've got a feelling you either bought very
        small or are frightened it will go down more at which
        point I'll say "hahaha" and you'll say "so what? I only
        bought 20 shares!"

      • Speaking of pipeline, latest out of just
        concluded San Francisco meetings indicated that ABT's new
        AIDS drug will have FDA sanction for early access
        program. That means physicians will get to use the drug on
        selected patients prior to full FDA approval. A good start
        for the most potent drug of this class.
        Also, a
        new antibiotic in final clinical trials was effective
        against respiratory bacteria resistant to macrolides such
        as Biaxin (ABT) and Zithromax (PFE). This drug would
        compete favorably with Zithromax (i.e. single dosage,
        short treatment and broad spectrum).
        Finally, there
        is still life for Biaxin which was competing for
        narrow spectrum with quinolines such as PFE's Trovan.
        Recent problems with toxicity of Trovan and quinolines
        in general makeing fallback to safer macrolides
        appealing.
        Digest those facts.

 
ABT
44.25+0.09(+0.20%)Nov 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.